In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Neurocrine, with a price target of $180.00. The company’s shares closed yesterday at $137.35.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Bansal is a 4-star analyst with an average return of 9.2% and a 58.72% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Eli Lilly & Co, and AbbVie.
Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $168.61, representing a 22.76% upside. In a report released on October 9, UBS also maintained a Buy rating on the stock with a $195.00 price target.
The company has a one-year high of $154.61 and a one-year low of $84.23. Currently, Neurocrine has an average volume of 886K.
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine price target raised to $195 from $188 at UBS
- Neurocrine presents new data from KINECT-HD2 study of ingrezza
- Neurocrine’s ingrezza shows efficacy in tardive dyskinesia
- Promising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine Biosciences
- Neurocrine price target raised to $169 from $160 at Jefferies
/AI%20(artificial%20intelligence)/AI%20software%20engineering%20by%20Tapati%20Rinchumrus%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Apple%20Inc%20phone%20and%20data-by%20Anderson%20Reis%20via%20Shutterstock.jpg)